Dmitry Stambolsky

Dmitry Stambolsky

Auto-generated profile, based on publicly available information

Dmitry Stambolsky

Lomonosov Moscow State University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
MKMaxim Karagyaur
Maxim Karagyaur
ARAlexandra Rostovtseva
Alexandra Rostovtseva
ESEkaterina Semina
Ekaterina Semina
PKPolina Klimovich
Polina Klimovich
VBVadim Balabanyan
Vadim Balabanyan
VTVsevolod Tkachuk
Vsevolod Tkachuk
Timely nerve restoration is an important factor for the successful regeneration of tissues and organs. It is known that axon regeneration following nerve injury is a multifactorial process that depends on the local expression of neurotrophins, including brain-derived neurotrophic factor (BDNF). Along with the survival of neurons, the active reorganization of the extracellular matrix is an important step for the growth of axons to their targets. Urokinase serine protease is part of the plasminogen activator system, which provides the vectoriality of the process of fibrinolysis and matrix reorganization, facilitating the growth of nerves to their targets. Based on this and in view of the results of our previous studies, we suggest that a combined bicistronic plasmid encoding the complementary proteins BDNF and urokinase may be beneficial in nerve regeneration. The ability of this bicistronic plasmid to stimulate nerve restoration was confirmed by in vitro stimulation of Neuro2a neurite growth and in vivo nerve conductivity and histology studies. To our knowledge, this is the first article that demonstrates the effectiveness of a bicistronic plasmid containing the human genes BDNF and uPA in the regeneration of the injured peripheral nerve. The results obtained demonstrate that plasmid vectors encoding several complementary-active therapeutic proteins may serve as a basis for developing prospective treatments for a wide range of multicomponent neural system disorders, such as nerve trauma. SIGNIFICANCE STATEMENT This study is the first to show the effectiveness of using a bicistronic plasmid encoding complementary-active human proteins brain-derived neurotrophic factor (hBDNF) and urokinase plasminogen activator (huPA) in the regeneration of the crushed peripheral nerve in a murine model.

8 June 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
SDStalik Dzhauari
Stalik Dzhauari
SLSvetlana A. Litvinova
Svetlana A. Litvinova
AEAnastasia Efimenko
Anastasia Efimenko
NANatalya Alexandrushkina
Natalya Alexandrushkina
NBNataliya Basalova
Nataliya Basalova
MKMaxim Karagyaur
Maxim Karagyaur
Brain-derived neurotrophic factor (BDNF) is a classic neuroprotective and pro-regenerative factor in peripheral and central nervous tissue. Its ability to stimulate the restoration of damaged nerve and brain tissue after ischemic stroke and intraventricular hemorrhage has been demonstrated. However, the current concept of regeneration allows us to assert that one factor, even if essential, cannot be the sole contributor to this complex biological process. We have previously shown that urokinase-type plasminogen activator (uPA) complements BDNF activity and stimulates restoration of nervous tissue. Using a model of intracerebral hemorrhage in rats, we investigated the neurotrophic and neuroprotective effect of BDNF combined with uPA. The local simultaneous administration of BDNF and uPA provided effective neuroprotection of brain tissue after intracerebral hemorrhage, promoted survival of experimental animals and their neurological recovery, and decreased lesion volume. The study of cellular mechanisms of the observed neurotrophic effect of BDNF and uPA combination revealed both known mechanisms (neuronal survival and neurite growth) and new ones (microglial activation) that had not been shown for BDNF and uPA. Our findings support the concept of using combinations of biological factors with diverse but complementary mechanisms of action as a promising regenerative approach.

21 December 2018 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ДСД. В. Стамбольский
Д. В. Стамбольский
EBE. V. Bryzgalina
E. V. Bryzgalina
AEAnastasia Efimenko
Anastasia Efimenko
KAK. Yu. Alasania
K. Yu. Alasania
ESE. M. Shkomova
E. M. Shkomova
SMSimon Matskeplishvili
Simon Matskeplishvili
Further progress in medicine is closely related to the clinical introduction of regenerative technologies, including cell therapy. Presented article covers the ethical and legal status of obtaining an informed consent from donors of cell material. The manuscript defines specific functions of such informed consent related to the features of research object and possibilities of its further use. The recommended content of the informed consent from cell material donors is determined in the context of global trends as well as guidelines for obtaining the consent. Existing difficulties and contradictions while developing an informed consent are presented

1 June 2021 in Tissue Engineering Part C: Methods
Verified
Journal Article
Closed access
MKMaxim Karagyaur
Maxim Karagyaur
ARAlexandra Rostovtseva
Alexandra Rostovtseva
SDStalik Dzhauari
Stalik Dzhauari
EKEvgeniy Kozlov
Evgeniy Kozlov
LLLyubov Lebedeva
Lyubov Lebedeva
DSDmitry Stambolsky
Dmitry Stambolsky
Gene therapy is one of the promising approaches for regenerative medicine. Local and long-term expression of essential growth factors allows to achieve the desired therapeutic effect. However, some aspects of prolonged usage of genetic constructs encoding growth factors, such as toxicity, mutagenicity, genotoxicity, and ability to disseminate from the injection site and mediate ectopic expression of therapeutic proteins, are poorly investigated. These aspects of gene therapy drugs' usage became the subject of this study. To study plasmid biodistribution, toxicity, mutagenicity, and genotoxicity, we used previously described bicistronic genetic construct encoding human brain-derived neurotrophic factor (hBDNF) and human urokinase plasminogen activator (huPA) for nerve repair. Biodistribution studies were conducted in mice: a course of intramuscular plasmid injections was followed by the study of the content of the plasmid (real-time polymerase chain reaction) and recombinant proteins (enzyme-linked immunosorbent assay) in murine organs and tissues. The study of the plasmid chronic toxicity was carried out on rats with registration of their weight dynamics, neurological status, emotional state, and blood test parameters. The mutagenicity of the plasmid was studied in an in vivo DNA comet test in mice. Plasmid genotoxicity was investigated in the model of somatic recombination in Drosophila females. We have shown that plasmids can disseminate from the injection site, but do not mediate ectopic expression of growth factors upon repeated intramuscular injections. The studied plasmid also does not reveal toxic, mutagenic, or genotoxic effects. During the toxicological study on rats, we have shown that daily injections of this genetic construct, despite its ability to disseminate from the injection site, do not affect the physical, cognitive, and emotional state of experimental animals. We have demonstrated the safety of the bicistronic plasmid, encoding hBDNF and huPA, upon its repeated administration. The properties of genetic constructs strongly depend on their sequence and delivery approach, which requires conducting of their safety studies in each specific case. Impact statement: Gene therapy is one of the promising approaches for regenerative medicine. Local and long-term expression of essential growth factors allows to achieve the desired therapeutic effect. However, some aspects of prolonged usage of genetic constructs encoding growth factors, such as toxicity, mutagenicity, genotoxicity, and ability to disseminate from the injection site and mediate ectopic expression of therapeutic proteins, are poorly investigated. These aspects of gene therapy became the subject of this study. To our knowledge, this is a unique study that provides a thorough safety investigation of a bicistronic plasmid after its readministration.

6 July 2022 in Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Open access
PDF file
SDS. S. Dzhauari
S. S. Dzhauari
MKMaxim Karagyaur
Maxim Karagyaur
VBV. Yu. Balabanyan
V. Yu. Balabanyan
MSM. N. Skryabina
M. N. Skryabina
APAlexandra Leonidovna Primak
Alexandra Leonidovna Primak
ВБВ. Ю. Балабаньян
В. Ю. Балабаньян
Relevance. The use of gene therapy drugs for the treatment of genetic diseases and stimulation of regeneration processes is lengthy and involves repeated injections, which may lead to increased dissemination of gene therapy constructs from the injection site and undesirable ectopic expression of growth factors encoded in them. Existing approaches to study the pharmacokinetics of a drug to assess the dissemination of a gene therapy drug from the site of administration are not applicable. Objective: to evaluate the suitability of the real-time PCR method for studying the biodistribution of a promising gene therapy drug in mice during a course of use. Methods. Male F1 CBA×C57/Black mice after nerve injury were injected with the test plasmid into the denervated tibial muscle after nerve injury, as well as after 4, 9 and 13 days at a dosage of 60 and 120 μg/mouse. After 7, 14, and 28 days, organ and tissue samples were removed, total DNA was isolated, and plasmid DNA content was assessed by real-time PCR. Results. We have shown that the studied genetic construct is able to disseminate from the injection site. We have found that the peak of dissemination for this construct in the organs and tissues of the mouse is reached 14–28 days after the end of the course application, while ectopic expression of growth factors is not observed in them. Conclusion. The proposed method is specific, highly sensitive, and linear over a wide range of concentrations. Thus, it can be recommended for studying the biodistribution of potential gene therapy drugs in the body of experimental animals as part of a preclinical studies complex.

2 February 2023 in Problems of Biological, Medical and Pharmaceutical Chemistry
Verified
Journal Article
Closed access
MKMaxim Karagyaur
Maxim Karagyaur
ARA.I. Rostovtseva
A.I. Rostovtseva
PKP.S. Klimovich
P.S. Klimovich
VBV.YU. Balabanyan
V.YU. Balabanyan
DSD.V. Stambolsky
D.V. Stambolsky
Traumatic nerve injury is one of the most common cause of permanent disability. The problem of nerve regeneration is based on the slow growth of nerve fibers and short-term production of neutrophic factors (NGF, BDNF, NT-3, GDNF, etc.), which stimulate the survival of damaged neurons and growth of nerve fibers. In most cases, the intrinsic regenerative potential is insufficient to restore innervation, which requires the replacement therapy with neurotrophins. One of the most promising therapeutic approaches for regenerative medicine is gene therapy that allows to prolong the local production of neurotrophic factors. Previously, we created a bicistronic gene therapy construct pNCure (a plasmid for the treatment of nerves), based on the modified pVax1 plasmid construct approved by the FDA (U.S. Food and Drug Administration), and encoding the cDNA sequences of brain-derived neurotrophic factor (BDNF) and urokinase-type plasminogen activator (uPA). It revealed a prominent therapeutic activity in a model of traumatic nerve injury in mice. Gene therapy products is a particular class of drugs that need particular approaches to production, purification and standartization. There is practically no information on the purification and standardization of gene therapy drugs in Russian, and this is the topic of our manuscript. Here, we have elucidat-ed the issues of plasmid production in E. coli cells with subsequent multistage purification, as well as the issues of evaluation the identity and quantity of the plasmid (using PCR and UV spectrometry methods), and determination of pH and quantity of related and secondary impurities within the sub-stance. The results of the study have demonstrated that the proposed approach to plasmid production, purification and standartization allows to obtain the desired high-quality gene therapy drug that meets all the requirements of the XIV State Pharmacopia.